NCT04973163 2026-02-17
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
Boehringer Ingelheim
Phase 1 Active not recruiting
Boehringer Ingelheim
Bristol-Myers Squibb
Mirati Therapeutics Inc.
AstraZeneca
Eli Lilly and Company
AstraZeneca
Novartis
AstraZeneca
Hoffmann-La Roche
Genentech, Inc.